Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer

IF 1.9 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Breast Journal Pub Date : 2024-10-10 DOI:10.1155/2024/8851703

Miaomiao Jia, Haibo Yang, Lihui Pan, Jinnan Gao, Fan Guo

{"title":"Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer","authors":"Miaomiao Jia, Haibo Yang, Lihui Pan, Jinnan Gao, Fan Guo","doi":"10.1155/2024/8851703","DOIUrl":null,"url":null,"abstract":"<div>\n Purpose: We aimed to investigate whether estrogen receptor (ER) status affects the predictive role of the human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) score on the efficacy of neoadjuvant treatment for HER2-positive breast cancer.\n Methods: This retrospective study comprised 167 individuals diagnosed with HER2-positive invasive breast cancer who had undergone neoadjuvant treatment and surgery. Uni- and multivariable logistic regression analyses were performed on the relationship between the HER2 IHC score and total pathological complete response (tpCR), breast pathological complete response (bpCR), or axillary partial response (apCR). Subgroup analyses were used to investigate whether the relationship between the HER2 IHC score and tpCR, bpCR, or apCR differed by ER or PR status.\n Results: The overall tpCR rate for HER2-positive breast cancers treated with neoadjuvant treatment was 41.32% (69 of 167). The tpCR, bpCR, and apCR rates were greater in the HER2 IHC 3+ group (tpCR: IHC 3 + 47.69% vs. IHC 2 + 18.92%, p = 0.009). Significant interactions between HER2 IHC score and tpCR or bpCR were found in subgroup analyses based on ER status (tpCR: p for interaction = 0.001; bpCR: p for interaction = 0.001). Among ER-positive patients, the HER2 IHC 2+ group had substantially decreased tpCR, bpCR, and apCR rates than the HER2 IHC 3+ group (tpCR rate: p = 0.003; bpCR rate: p = 0.002; apCR rate: p = 0.002). For ER-negative individuals, the tpCR, bpCR, and apCR rates did not differ significantly among the HER2 IHC 3+ versus HER2 IHC 2+ groups. Similarly, interactions between HER2 IHC score and tpCR, bpCR, or apCR were found in subgroup analyses based on PR status.\n Conclusion: HER2 IHC 2+ may indicate a decreased tpCR rate, bpCR rate, and apCR rate to neoadjuvant treatment in HR-positive patients having HER2-positive breast cancer, but not in HR-negative patients.\n </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8851703","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/8851703","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We aimed to investigate whether estrogen receptor (ER) status affects the predictive role of the human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) score on the efficacy of neoadjuvant treatment for HER2-positive breast cancer.

Methods: This retrospective study comprised 167 individuals diagnosed with HER2-positive invasive breast cancer who had undergone neoadjuvant treatment and surgery. Uni- and multivariable logistic regression analyses were performed on the relationship between the HER2 IHC score and total pathological complete response (tpCR), breast pathological complete response (bpCR), or axillary partial response (apCR). Subgroup analyses were used to investigate whether the relationship between the HER2 IHC score and tpCR, bpCR, or apCR differed by ER or PR status.

Results: The overall tpCR rate for HER2-positive breast cancers treated with neoadjuvant treatment was 41.32% (69 of 167). The tpCR, bpCR, and apCR rates were greater in the HER2 IHC 3+ group (tpCR: IHC 3 + 47.69% vs. IHC 2 + 18.92%, p = 0.009). Significant interactions between HER2 IHC score and tpCR or bpCR were found in subgroup analyses based on ER status (tpCR: p for interaction = 0.001; bpCR: p for interaction = 0.001). Among ER-positive patients, the HER2 IHC 2+ group had substantially decreased tpCR, bpCR, and apCR rates than the HER2 IHC 3+ group (tpCR rate: p = 0.003; bpCR rate: p = 0.002; apCR rate: p = 0.002). For ER-negative individuals, the tpCR, bpCR, and apCR rates did not differ significantly among the HER2 IHC 3+ versus HER2 IHC 2+ groups. Similarly, interactions between HER2 IHC score and tpCR, bpCR, or apCR were found in subgroup analyses based on PR status.

Conclusion: HER2 IHC 2+ may indicate a decreased tpCR rate, bpCR rate, and apCR rate to neoadjuvant treatment in HR-positive patients having HER2-positive breast cancer, but not in HR-negative patients.

Abstract Image

查看原文本刊更多论文

雌激素受体对 HER2 免疫组化评分与 HER2 阳性乳腺癌新辅助治疗病理完全反应之间关系的影响

目的：我们旨在研究雌激素受体（ER）状态是否会影响人表皮生长因子受体 2（HER2）免疫组化（IHC）评分对 HER2 阳性乳腺癌新辅助治疗疗效的预测作用。研究方法这项回顾性研究包括167名确诊为HER2阳性浸润性乳腺癌并接受了新辅助治疗和手术的患者。对 HER2 IHC 评分与总病理完全反应（tpCR）、乳腺病理完全反应（bpCR）或腋窝部分反应（apCR）之间的关系进行了单变量和多变量逻辑回归分析。亚组分析用于研究 HER2 IHC 评分与 tpCR、bpCR 或 apCR 之间的关系是否因 ER 或 PR 状态而异。结果接受新辅助治疗的HER2阳性乳腺癌的总体tpCR率为41.32%（167例中有69例）。HER2 IHC 3+ 组的 tpCR、bpCR 和 apCR 率更高（tpCR：IHC 3 + 47.69% vs. IHC 2 + 18.92%，p = 0.009）。在基于ER状态的亚组分析中发现，HER2 IHC评分与tpCR或bpCR之间存在显著的交互作用（tpCR：交互作用的p = 0.001；bpCR：交互作用的p = 0.001）。在ER阳性患者中，HER2 IHC 2+组的tpCR、bpCR和apCR率大大低于HER2 IHC 3+组（tpCR率：p = 0.003；bpCR率：p = 0.002；apCR率：p = 0.002）。对于ER阴性个体，HER2 IHC 3+组与HER2 IHC 2+组之间的tpCR率、bpCR率和apCR率没有显著差异。同样，在基于 PR 状态的亚组分析中，也发现了 HER2 IHC 评分与 tpCR、bpCR 或 apCR 之间的相互作用。结论对于HR阳性的HER2阳性乳腺癌患者来说，HER2 IHC 2+可能会降低新辅助治疗的tpCR率、bpCR率和apCR率，但对于HR阴性的患者来说则不会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Journal 医学-妇产科学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include: Risk Factors Prevention Early Detection Diagnosis and Therapy Psychological Issues Quality of Life Biology of Breast Cancer.